Serious adverse effects
Bacillus Calmette‐Guérin (BCG) showed no clear difference in serious adverse effects compared with mitomycin C (MMC) (low certainty).
1 finding from 1 review
Time to recurrence
Bacillus Calmette‐Guérin (BCG) showed no clear difference in time to recurrence (absolute effect size estimates based on event… compared with mitomycin C (MMC) (low certainty).
1 finding from 1 review
Time to progression
Bacillus Calmette‐Guérin (BCG) showed no clear difference in time to progression (absolute effect size estimates based on event… compared with mitomycin C (MMC) (low certainty).
1 finding from 1 review
Quality of life (measured using EORTC QLQ‐BLS24 at baseline and after each installation weekly for 6 weeks)
1 finding from 1 review
Days missed from work or school · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
3 findings from 1 review
no estimate extracted
16 studies · 3799 participants
Very low
no estimate extracted
18 studies · 4183 participants
Very low
no estimate extracted
3 studies · 1005 participants
Very low
Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Proportion of participants experiencing adverse events · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Effectiveness Proportion of women with perception of improvement of bleeding symptoms · HMB
Endometrial resection or ablation probably leads to lower effectiveness Woman's perception (proportion with improvement in… compared with open hysterectomy (moderate certainty).
1 finding from 1 review
Acceptability Proportion satisfied with treatment · heavy menstrual bleeding
Endometrial resection or ablation probably leads to lower acceptability Proportion satisfied with treatment compared with minimally invasive hysterectomy (moderate certainty).
1 finding from 1 review
Safety Any serious adverse event · heavy menstrual bleeding
Endometrial resection or ablation showed no clear difference in safety Any serious adverse event compared with minimally invasive hysterectomy (moderate certainty).
1 finding from 1 review
Return to normal activity · heavy menstrual bleeding
1 finding from 1 review
no estimate extracted
99 participants
GRADE not reported
Quality of life SF‐36 at 2 years – general health perception · HMB
1 finding from 1 review
Requirement for further surgery for treatment failure within 1 year after surgery · HMB
1 finding from 1 review
Acceptability Proportion satisfied with treatment · HMB
Endometrial resection or ablation showed no clear difference in acceptability Proportion satisfied with treatment compared with open hysterectomy (moderate certainty).
1 finding from 1 review
Safety Any serious adverse event · HMB
Endometrial resection or ablation showed no clear difference in safety Any serious adverse events compared with open hysterectomy (low certainty).
1 finding from 1 review
Return to normal activity · HMB
1 finding from 1 review
Effectiveness · heavy menstrual bleeding
Endometrial resection or ablation showed no clear difference in effectiveness compared with minimally invasive hysterectomy (low certainty).
1 finding from 1 review
Quality of life · heavy menstrual bleeding
1 finding from 1 review